Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Austria.
Institute of Pharmacology and the Gaston H. Glock Research Laboratories for Exploratory Drug Development, Center of Physiology and Pharmacology, Medical University of Vienna, Austria
Mol Pharmacol. 2022 Feb;101(2):95-105. doi: 10.1124/molpharm.121.000413. Epub 2021 Dec 5.
Folding-deficient mutants of solute carrier 6 (SLC6) family members have been linked to human diseases. The serotonin transporter [(SERT)/SLC6A4] is an important drug target in the treatment of depression, anxiety, and obsessive-compulsive disorders and-with structural information in several conformational states-one of the best understood transporters. Here, we surmised that thermal unfolding offered a glimpse on the folding energy landscape of SLC6 transporters. We carried out molecular dynamic (MD) simulations to understand the mechanistic basis for enhanced and reduced stability, respectively, of the thermostabilized variant SERT-Y110A/I291A/T439S, which had previously been used for crystallization of human SERT in the outward-facing state, and of the folding-deficient SERT-P601A/G602A. We also examined the hydrophobic mismatch caused by the absence of cholesterol to explore the contribution of cholesterol to protein stability. When compared with wild type SERT, the thermodynamic and kinetic stability of SERT-Y110A/I291A/T439S was enhanced. In the other instances, changes in these two components were not correlated: the mutations in SERT-P601A/G602A led to a drop in thermodynamic but an increase in kinetic stability. The divergence was even more pronounced after cholesterol depletion, which reduced thermodynamic stability but increased the kinetic stability of wild type SERT to a level comparable to that of SERT-Y110A/I291A/T439S. We conclude that the low cholesterol content of the endoplasmic reticulum facilitates progression of the folding trajectory by reducing the energy difference between folding intermediates and the native state. SIGNIFICANCE STATEMENT: Point mutations in solute carrier 6 (SLC6) family members cause folding diseases. The serotonin transporter [(SERT)/SLC6A4] is a target for antidepressants and the best understood SLC6. This study produced molecular dynamics simulations and examined thermal unfolding of wild type and mutant SERT variants to understand their folding energy landscape. In the folding-deficient SERT-P012A/G602A, changes in kinetic and thermodynamic stability were not correlated. Similarly, cholesterol depletion lowered thermodynamic but enhanced kinetic stability. These observations allow for rationalizing the action of pharmacochaperones.
溶质载体 6(SLC6)家族成员的折叠缺陷突变与人类疾病有关。5-羟色胺转运体 [(SERT)/SLC6A4] 是治疗抑郁症、焦虑症和强迫症的重要药物靶点,并且——结合几种构象状态的结构信息——是了解最透彻的转运体之一。在这里,我们推测热失稳提供了 SLC6 转运体折叠能量景观的一个 glimpse。我们进行了分子动力学 (MD) 模拟,以分别理解热稳定变体 SERT-Y110A/I291A/T439S 的增强和降低稳定性的机制基础,该变体先前用于结晶人类 SERT 的外向构象,以及折叠缺陷 SERT-P601A/G602A。我们还研究了由于缺乏胆固醇而导致的疏水性失配,以探索胆固醇对蛋白质稳定性的贡献。与野生型 SERT 相比,SERT-Y110A/I291A/T439S 的热力学和动力学稳定性增强。在其他情况下,这两个组件的变化没有相关性:SERT-P601A/G602A 中的突变导致热力学稳定性下降,但动力学稳定性增加。在胆固醇耗竭后,这种差异更加明显,胆固醇耗竭降低了野生型 SERT 的热力学稳定性,但将其动力学稳定性提高到与 SERT-Y110A/I291A/T439S 相当的水平。我们得出的结论是,内质网中的低胆固醇含量通过降低折叠中间体与天然状态之间的能量差来促进折叠轨迹的进展。意义声明:溶质载体 6(SLC6)家族成员中的点突变导致折叠疾病。5-羟色胺转运体 [(SERT)/SLC6A4] 是抗抑郁药的靶点,也是了解最透彻的 SLC6。本研究进行了分子动力学模拟,并检查了野生型和突变 SERT 变体的热失稳,以了解它们的折叠能量景观。在折叠缺陷 SERT-P012A/G602A 中,动力学和热力学稳定性的变化没有相关性。同样,胆固醇耗竭降低了热力学稳定性,但增强了动力学稳定性。这些观察结果允许合理化药理伴侣的作用。